Alcami completes its acquisition of Tjoapack, creating a 1,400-strong CDMO with over one million square feet of operations across the US and the Netherlands, adding European packaging scale and QP release services.
Alcami, a contract development and manufacturing organization (CDMO), recently announced the resignation of its CEO, Bill Humphries. Alcami’s Board Chair and former CEO Patrick Walsh will serve as Interim CEO, ensuring the continuation of smooth operations.
Bill Humphries, CEO of Alcami, shares his vision for the future, discussing dynamic market trends and the company’s commitment to innovation. Under his leadership, Alcami is poised to redefine the pharmaceutical and biotechnology landscape, focusing on cutting-edge solutions and navigating global complexities. This conversation highlights Alcami’s strategic direction, accomplishments, and upcoming challenges.
UK specialist healthcare investor GHO Capital Partners and US investment firm The Vistria Group have entered into an agreement to buy a controlling interest in US CDMO Alcami from current private equity owners Madison Dearborn Partners (MDP) and Ampersand Capital Partners. Financial terms of the deal were not disclosed.
Growth in the global oncology drug market is an important measure of opportunities in drug development and manufacturing, including for contract manufacturers of active pharmaceutical ingredients (APIs) and finished drug products.
